



Neuro-SysMed

# Newsletter

Oct 2024

## DIRECTORS COMMENTS

Dear all

As our Center continues on its scientific trajectory, we are delighted to share some highlights and milestones from our recent activities. Our 2nd Annual Symposium held at Solstrand Hotel was a great success, gathering 125 participants from across the globe to engage in knowledge-sharing and strategic discussions. The symposium highlighted our unwavering commitment to advancing translational and clinical research towards new therapeutic breakthroughs in multiple sclerosis, neurodegenerative parkinsonisms and dementias, and amyotrophic lateral sclerosis. We extend our gratitude to all our attendees, speakers, and our esteemed Scientific Advisory Board members, whose guidance and input continue to elevate our research agenda.

Our commitment to making a difference for these disease groups was also exemplified through our participation in Arendalsuka, Norway's foremost forum for public policy and debate. Neuro-SysMed team members contributed to important discussions on clinical trials. Engaging with policymakers, healthcare leaders, and patient advocacy groups, we underscored the need for regulatory improvements to expedite clinical research and ensure access to cutting-edge treatments.

On the research front, we have made substantial progress, with several notable new papers across the Neuro-SysMed groups and significant progress in our ongoing trials, as well embarking on new and even bolder endeavors towards neuroprevention.

Thank you to all our partners, collaborators, and team members for your dedication and enthusiasm.

Warm regards,

Charalampos Tzoulis & Kjell-Morten Myhr



Neuro-SysMed



Centre for  
Clinical Treatment  
Research

# ANNUAL SYMPOSIUM

Neuro-SysMed hosted its 2nd Annual Symposium during September 30 and October 1, 2024, also this time at the historic Solstrand Hotel outside of Bergen. Altogether 125 participants from the Neuro-SysMed research fields, in a very international mix, enjoyed scientific talks, discussions, posters and mingling, and not least Solstrand's beautiful surroundings and delicious cuisine.

Besides being the Neuro-SysMed event of the year, the annual symposium is part of the course NEUROSYSM920 - Neuro-SysMed seminars and symposium, at the Neuro-SysMed Research School for Translational Neuroscience.

The Neuro-SysMed Directors Kjell-Morten Myhr and Charalampos Tzoulis opened the program of the symposium with a talk on current challenges in clinical trials in MS and neurodegeneration, touching upon today's status on therapies, particular challenges and areas of research, including Neuro-SysMed's current projects and a discussion on design of future clinical trials.

Neuro-SysMed used the opportunity to have strategy meetings with participating members of the Scientific Advisory Board (SAB), including Raymond Koopmans and Xavier Montalban. The SAB expressed clear support for Neuro-SysMed's research and provided valuable advice and suggestions for further developments. [Read more about the symposium here.](#)





## K.G JEBSEN CENTRES ANNUAL RETREAT 2024

Every year, the K.G. Jebsen Centres from all around Norway meet for a retreat. It is an interesting gathering because centres focus on completely different research fields. Thus, these gatherings must have a common topic that transcends research fields and is equally interesting for everyone. In October 2024, the K.G. Jebsen for Parkinson's Disease, led by Prof. Tzoulis, is responsible for organizing the event. The topic was ***Innovation and commercialization in medicine: turning laboratory discoveries into inventions and real-world treatments.*** Leaders from 6 active centres and 20 former K.G. Jebsen Centres joined and the event was held in Solstrand, on 22<sup>nd</sup>-23<sup>rd</sup> October.



## THE ITALIAN'S MS SOCIETY'S ANNUAL SCIENTIFIC CONGRESS 2024

On May 28th, the Italian MS Society hosted the Annual Scientific Congress 2024. Notable attendees included Neuro-SysMed director Kjell-Morten Myhr, and Prof. Øivind Torkildsen. In addition to other members of the Horizon Europe funded project EBV-MS (led by Myhr and Torkildsen).

The overarching theme and the topic for the first day of the congress was "Brain Health: Rethinking Diagnosis of Multiple Sclerosis and Related Disorders. Prof. Kjell-Morten Myhr was invited as a guest speaker and held a presentation titled: "Targeting Epstein-Barr Virus Infection for Prevention of MS Progression: The Case of the EBV-MS EU Project." He introduced the exciting EBV-MS project, and discussed how the relationships between EBV and multiple sclerosis are studied, possible treatments, and potential prevention strategies. [Read more here.](#)



Photos: AISM, Associazione Italiana SM

# NEURO-SYSMED AT ARENDALSUKA

Neuro-SysMed actively participated in two key debates during Arendalsuka, which were on the topics of clinical trials and the future of MS treatment.

## Debate on Clinical Trials

The first debate took place in the "Brain Tent," focusing on the regulatory framework for conducting clinical treatment studies within specialized healthcare services. The central question was: How can we better achieve the goals of the National Action Plan for Clinical Studies? Neuro-SysMed, alongside representatives from the Norwegian MS Society, the Norwegian Brain Council, NorTrials, Novartis, and the Ministry of Health and Care Services, contributed to a constructive discussion. The Ministry of Health and Care Services's new State Secretary, Usman Ahmad Mushtaq, expressed significant interest

in the challenges and committed to incorporating insights from the debate into the ongoing evaluation of both the action plan and the NorTrials initiative.

Among the engaged panel members were Nicolas E. Vaugelade-Baust from NorTrials/Novartis, Charalampos Tzoulis (Neuro-SysMed), State Secretary Usman Ahmad Mushtaq from the Ministry of Health and Care Services, Kjell-Morten Myhr (Neuro-SysMed), Jan Anders Istad from the Norwegian MS Society, and Henrik Persson from the Norwegian Brain Council.



## Debate on the Future of MS Treatment

Guided by the Norwegian MS Society's vision of "a world without MS," Øyvind Torkildsen presented the current state of MS treatment. This led to a lively debate on how to optimize existing treatments and simultaneously drive research-based advancements towards new therapies that bring us closer to this goal. Ole Johan Borge from the Research Council of Norway highlighted Norway's substantial national investment in brain health, with 800 million NOK allocated in 2023. He also emphasized the high quality of Norwegian research environments. Both the research communities and the MS Society called for continued efforts to reach the ambitious vision of a future without MS.

Through collaboration and engagement across sectors, Neuro-SysMed continues its important work to advance clinical studies and develop improved treatment options for MS.

Picture from the left: Øyvind Torkildsen, Neuro-SysMed and University of Bergen; Hanne F. Harbo, University of Oslo; Kjell-Morten Myhr, Neuro-SysMed and University of Bergen; Ole Johan Borge, Research Council of Norway; Magne Wang Fredriksen and Jan Anders Istad, Norwegian MS Society.





# RECENT PUBLICATIONS

## Recent publications from 2024

### [Molecular landscape of the overlap between Alzheimer's disease and somatic insulin-related diseases.](#)

**Ruisch IH, Widomska J, De Witte W, Mota NR, Fanelli G, Van Gils V, Jansen WJ, Vos SJB, Fóthi A, Barta C, Berkel S, Alam KA, Martinez A, Haavik J, O'Leary A, Slattery D, Sullivan M, Glennon J, Buitelaar JK, Bralten J, Franke B, Poelmans G.**

*Alzheimers Res Ther.* 2024 Oct 28;16(1):239. doi: 10.1186/s13195-024-01609-2. PMID: 39465382.

### [Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study.](#)

**Hillert J, Butzkueven H, Magyari M, Wergeland S, Moore N, Soilu-Hänninen M, Ziemssen T, Kuhle J, Pontieri L, Forsberg L, Aarseth JH, Zhu C, Sicignano N, Mushnikov V, Bezemer I, Sabidó M.**

*Clin Epidemiol.* 2024 Oct 17;16:717-732. doi: 10.2147/CLEP.S480525. eCollection 2024. PMID: 39435029 Free PMC article.

### [The Therapeutic Potential of Exosomes from Mesenchymal Stem Cells in Multiple Sclerosis.](#)

**Kråkenes T, Sandvik CE, Ytterdal M, Gavasso S, Evjenth EC, Bø L, Kvistad CE.**

*Int J Mol Sci.* 2024 Sep 24;25(19):10292. doi: 10.3390/ijms251910292. PMID: 39408622 Free PMC article. Review.

### [The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis.](#)

**Coerver E, Schoof L, Hogenboom L, Wessels M, van Ruyven P, van Samkar A, Mostert J, van Kempen Z, van Oosten BW, Wokke BH, Tallantyre E, Myhr KM, Torkildsen O, Killestein J, Smets I, Strijbis E.**

*Mult Scler Relat Disord.* 2024 Sep 28;91:105900. doi: 10.1016/j.msard.2024.105900. Online ahead of print. PMID: 39369631

### [Amyotrophic lateral sclerosis caused by the C9orf72 expansion in Norway - prevalence, ancestry, clinical characteristics and sociodemographic status.](#)

**Olsen CG, Malmberg VN, Fahlström M, Alstadhaug KB, Bjørnå IK, Braathen GJ, Bråthen G, Demic N, Hallerstig E, Hogenesch I, Horn MA, Kampman MT, Kleveland G, Ljøstad U, Maniaol A, Morsund ÅH, Nakken O, Schlüter K, Schuler S, Seim E, Flemmen HØ, Tysnes OB, Holmøy T, Høyer H.**

*Amyotroph Lateral Scler Frontotemporal Degener.* 2024 Sep 24:1-9. doi: 10.1080/21678421.2024.2405118. Online ahead of print. PMID: 39316038

### [Brain Proteome Profiling Reveals Common and Divergent Signatures in Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy.](#)

**Dick F, Johanson GAS, Tysnes OB, Alves G, Dölle C, Tzoulis C.**

*Mol Neurobiol.* 2024 Aug 21. doi: 10.1007/s12035-024-04422-y. Online ahead of print. PMID: 39164482

### [Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson's Disease.](#)

**Pedersen CC, Ushakova A, Alves G, Tysnes OB, Blennow K, Zetterberg H, Maple-Grødem J, Lange J**  
*NPJ Parkinsons Dis.* 2024 Aug 21;10(1):162. doi: 10.1038/s41531-024-00768-1. PMID: 39164268 Free PMC article.

### [Orthostatic Hypotension and Risk of Mild Cognitive Impairment and Dementia in Parkinson's Disease.](#)

**Hiorth YH, Schulz J, Pedersen KF, Tysnes OB, Alves G.**

*Mov Disord Clin Pract.* 2024 Aug 6. doi: 10.1002/mdc3.14179. Online ahead of print. PMID: 39108067

### [Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients.](#)

**Torgauten HM, Onyango TB, Ljostveit S, Hallin EI, Serkland TT, Skrede S, Langeland N, Cox RJ, Wergeland S, Myhr KM, Torkildsen Ø.**

*Mult Scler Relat Disord.* 2024 Sep;89:105770. doi: 10.1016/j.msard.2024.105770. Epub 2024 Jul 15. PMID: 39029342

### [Activation of Neurotoxic Astrocytes Due to Mitochondrial Dysfunction Triggered by POLG Mutation.](#)

**Liang KX, Chen A, Kianian A, Kristiansen CK, Yangzom T, Furriol J, Høyland LE, Ziegler M, Kråkenes T, Tzoulis C, Fang EF, Sullivan GJ, Bindoff LA.**

*Int J Biol Sci.* 2024 May 11;20(8):2860-2880. doi: 10.7150/ijbs.93445. eCollection 2024. PMID: 38904024 Free PMC article.

### [Dopamine synthesis and transport: current and novel therapeutics for parkinsonisms.](#)

**Tai MDS, Gamiz-Arco G, Martinez A.**

*Biochem Soc Trans.* 2024 Jun 26;52(3):1275-1291. doi: 10.1042/BST20231061. PMID: 38813865 Free PMC article. Review.

### [Neural regeneration in the human central nervous system-from understanding the underlying mechanisms to developing treatments. Where do we stand today?](#)

**Kvistad CE, Kråkenes T, Gavasso S, Bø L.**

*Front Neurol.* 2024 May 9;15:1398089. doi: 10.3389/fneur.2024.1398089. eCollection 2024. PMID: 38803647 Free PMC article. Review.

### [Exploring active ageing in a community-based living environment: an ethnographic study in the Western Norway context.](#)


**Førsund E, Torrado Vidal JC, Fæø SE, Reithe H, Patrascu M, Husebo BS.**

*Front Public Health.* 2024 Apr 30;12:1380922. doi: 10.3389/fpubh.2024.1380922. eCollection 2024. PMID: 38745999 Free PMC article.

## OTHER NEWS: Research highlights

### Confirming the key role of the C-terminal eight residues of DNAJC12 in TH binding

Pathogenic variants of the J-domain protein and Hsp70 cochaperone DNAJC12 cause parkinsonism, which is associated with a defective interaction of DNAJC12 with tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine (DA) biosynthesis. In recent work, the Martinez group is elucidating of the structure of the complex of tyrosine hydroxylase and DNAJC12 by cryoelectron microscopy and cross-linking MS, revealing the stabilizing effect of the chaperone effect of DNAJC12 on TH and explaining the pathogenic mechanism of the disease variants of leading to parkinsonism. [See preprint in Research Square.](#)



### New knowledge of mechanisms associated with degenerative parkinsonisms

The disease-processes underlying progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), two severe and very different forms of degenerative parkinsonism, are unknown. In a first-of-its-kind study, we carried out proteomics analyses on fresh-frozen brain tissue from individuals with PD, PSP, and MSA. We identified a strong mitochondrial signal in PD and PSP, which was more pronounced in the latter. However, this was not observed in MSA, which was mainly associated with immunological/inflammatory pathways. These findings advance the knowledge of the mechanisms associated with degenerative parkinsonisms and highlight potential therapeutic targets. [The study was published in Molecular Neurobiology.](#)



### Optimizations ongoing of new CLARIOstar

***a-syn seeding amplification assay (a-syn SAA):*** In the previous Neuro-SysMed Newsletter it was announced that Prof. Tzoulis, Dr. Riemer and Prof. Tysnes have been granted an equipment fund that was used to purchase the CLARIOstar fluorescence reader, for the establishment of the  $\alpha$ -synuclein seed amplification assay ( $\alpha$ Syn-SAAs). Experiments on CSF samples have started and as with any new technique, the assay is going through optimization steps in Prof. Tzoulis group. Despite a few obstacles to overcome, optimizations finally started to work and technical issues are improving with each new experiment. Hopefully, we will be able to share many good results on the next Issue of this Newsletter!



# Funding

## New project support:

The Drug discovery group with Aurora Martinez has obtained funding for the project "Exploring HIT1 Derivatives for Parkinson's Disease Therapy" from the Research Council of Norway program KOMMERSFORSK and by Vis Innovasjon. Involved investigators are Aurora Martinez, Charalampos Tzoulis, Svein Isungset Støve and Kunwar Jung KC.

The PD group can announce that the project "NADage – Boosting NAD metabolism to prevent pathological brain aging" is now fully funded thanks to funding from the Dam Foundation and from the ERA4Health program. The study, led by Prof. Tzoulis and coordinated by Katarina Lundervold, will investigate the effect of NAD supplementation in elderly people with frailty, a condition often associated with increased susceptibility to disease and functional decline. The European project is an international collaboration coordinated by Haukeland University Hospital and with UiB as a partner, together with international partners from Spain, Estonia and Denmark.

## Other centre updates



The Drug Discovery group had strong attendance at the [Annual Symposium of the Society for the Study of Inborn Errors of Metabolism \(SSIEM\)](#); Porto (Portugal), 3-6, September 2024.

They had five posters and organized a round table-discussion on pharmacological chaperone treatment for PKU.

## Best talk award

Congratulations to PhD candidate Mary Dayne Sia Tai for the prize for best talk at the [BioCat Annual Conference 2024](#) in Stavanger!



## New doctoral defense

On 5th June 2024, Nelson Osuagwu defended his PhD thesis entitled "Molecular mechanisms of mitochondrial dysfunction in neurodegenerative diseases". Supervisors were Professor Charalampos Tzoulis and PhD Christian Dölle. Congratulations!

## Interactive testlab at the Research Fair

We invited the audience to learn about the complexity of the brain, see brain tissue in a microscope, check their reflexes, and much more at our Research Fair stand September 20 and 21. The general topic of the Research Fair this year was Health, so naturally we needed to participate. Our fabulous crew had very busy days with lots of curious audience — thank you for a great job!





## New equipment

The microfluidic instrument Chromium iX (from 10X Genomics) has now been purchased for single cell and single nuclei RNA sequencing experiments. The equipment was purchased by a split contribution between Prof. Tzoulis, Prof. Bjørn Tore Gjersten, Prof. Simona Chera, Prof. Hans Petter Marti and associate professor Øystein Eirkrem. To assist on the single cell projects with Chromium iX, the cell counter LUNA-FL was recently purchased. It will automate counting and consequently, allow more samples to be processed simultaneously.



## Prestigious membership for Professor Tzoulis

Prof. Tzoulis has formally been appointed a full member of [the International Linked Clinical Trials \(iLCT\) committee for Parkinson's disease](#). This is a committee of world leading scientists, clinicians, and patient advocates, all experts in their field of Parkinson's research. The mission of the iLCT committee is to evaluate candidate disease modifying therapies for Parkinson's disease, prioritize them according to their readiness and potential, and position them for clinical testing.

## Contribution to UNESCO

Prof. Tzoulis has been invited to represent Norway on a [UNESCO commission](#) tasked with drafting a report and recommendation to global government on the responsible use of neurotechnology.



## ECTRIMS attendance and Best Presentation

From September 18th to 20th, 2024, members of the MS group participated in the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the world's largest MS congress, held in Copenhagen, Denmark. ECTRIMS, Europe's leading MS organization, attracts experts globally to advance multiple sclerosis (MS) understanding and treatment.

A conference highlight was doctoral candidate [Brit Ellen Rød](#) who received the ["Young Investigator Award for Best Oral Presentation"](#) for her study comparing rituximab and cladribine treatments for relapsing-remitting MS. Congratulations to Brit Ellen!

[Read more about our ECTRIMS attendance here.](#)





# UPCOMING NEURO-SYSMED EVENTS

These - and later events - can be found in [the Neuro-SysMed calendar](#).



## NEUROSYSM940: The nature of disease and suffering and the goals of precision medicine

2 ECTS course aiming to facilitate curiosity, reflection and discussion about issues, ambiguities, and dilemmas of precision medicine.

**Responsible:** Caroline Engen, Jan Reinert Karlsen and Nina Agnetha Grytten Torkildsen. Send a request to [nina.torkildsen@uib.no](mailto:nina.torkildsen@uib.no) to ask for admission if you haven't registered already  
**When:** November 12, 13 and 22, 2024.  
**More info:** [on this link](#)



## SEMINAR ON MS

Welcome to Neuro-SysMed's monthly seminars! Topic this time will be on MS. Speaker will be announced later. Join us in the auditorium in Armauer Hansens Hus at 11:30-13:00 (lunch at 11:30-12:00).

Speaker and title will be announced later.

**Place:** the auditorium in Armauer Hansen Hus  
**Time:** Wed. November 27 at 11:30 - 13:00 (incl. lunch).  
**Registration:** through [this link](#)  
**Abstract:** [will be available here](#)



## JUNIOR SCIENTIST SYMPOSIUM

Explore new frontiers with the young Neuro-SysMed researchers in this excellent arena to obtain valuable skills in presentation techniques, engage in scientific discussions and take advantage of peer reviews and comments. Learn about current research within MS, Parkinson's disease, dementia and ALS! Senior researchers are also welcome. Lunch is included.



**When:** Friday November 29, 2024 at 09.00-13.00.  
**Where:** Aud. 4, BB building (campus Haukeland University Hospital)  
**Registration:** [through this link](#).  
**More info:** [will be available here](#).

## NEUROSYSM930: Applied bioinformatics and data analysis in medical research

Get the knowledge central for successful application of bioinformatics and data analysis in clinical research on human tissue.

**When:** December 4-6, 2024. Lunch will be provided.  
**Where:** Campus UiB / Haukeland University Hospital, personal attendance.  
**Registration:** Deadline was Sept. 1 in Studentweb. Send a request to [nina.torkildsen@uib.no](mailto:nina.torkildsen@uib.no) to ask for admission if you haven't registered already  
**More info:** Is available [on this page](#)



## SEMINAR ON PD

Welcome to Neuro-SysMed's monthly seminars! Topic this time will be on Parkinson's disease. Speaker will be announced later. Join us in the auditorium in Armauer Hansens Hus at 11:30-13:00 (lunch at 11:30-12:00).

Speaker and title will be announced later.

**Place:** the auditorium in Armauer Hansen Hus  
**Time:** Wed. December 11 at 11:30 - 13:00 (incl. lunch).  
**Registration:** through [this link](#)  
**Abstract:** [will be available here](#)



# NEW FACES & POSITIONS IN THE NEURO-SYSMED GROUPS



**Gloria Gamiz-Arco** did her doctoral work in the Sanchez-Ruiz's group, University of Granada. Her project was focused on the use of ancestral proteins as powerful tools to address important issues in evolution, and in biotechnological/biomedical scenarios. After her PhD, Gloria moved to Norway to develop the early stage of her postdoctoral training. Gloria is working in Aurora Martinez's lab (Biorecognition group), focusing on the relationship between molecular structure and function to understand human health and disease with the objective of developing new therapeutic options for correction of associated metabolic and neurological malfunctions. In particular, the goal of her project is the development of potential therapies for parkinsonism based on the role of the co-chaperone DNAJC12.



**Pablo García-Gonzalez** is a PhD candidate at the University of Barcelona, focusing on the genetic causes of neurodegenerative disorders. His research involves analyzing common genetic variants across the genome, integrating cerebrospinal fluid (CSF) multi-omics data, and performing deep long-range sequencing of the APOE locus. His interest on understanding the genetic etiology of Progressive Supranuclear Palsy (PSP) through genome-wide association studies (GWAS) led to his collaboration with Neuro-SysMed. During his time here, he will be involved in the analysis of brain tissue single-nuclei RNA sequencing data of PSP cases and controls, aiming to identify cell-type specific transcriptomic signatures associated to disease status, with a special interest in their interaction with known genetic risk loci of the disease.



**Kristin Bekken Sjøstad** holds a master's degree in Neuroscience Nursing. She recently joined Neuro-SysMed as a research nurse in the Parkinson's Disease group.



**Max Korbmacher** defended recently (May-2024) his doctoral thesis at Western Norway University of Applied Sciences on May 23, 2024, with the thesis "Disease and ageing biomarker identification from multimodal magnetic resonance imaging". He has previously a master's degree in neuroscience. He recently joined the MS Research Group to analyse the MRI dataset from the OFAMS-MS trial. He is aiming for a Post Doctoral Fellowship at our Centre.



**Andrea Kyvik Habbestad** joined the MS research group in August 2024, after finishing her 18-month internship as LIS-1 doctor. She has previously worked in the group and recently published an article on increasing age at onset of MS. She will join as a PhD candidate in the Horizon Europe-funded EBV-MS project - with a focus on antiviral therapy in MS.



**Regina Breinbauer** is a Master student studying Molecular Medicine, from Friedrich-Alexander University, Erlangen-Nuremberg, Germany. The master's program focuses on understanding human health at the molecular and cellular level, combining key fields like neuroscience, immunology and oncology, with a specialization in potential therapeutic interventions for diseases. During this fall 2024, she will be undertaking an ERASMUS+ traineeship at Neuro-SysMed as part of the Bergen MS Research Group, collaborating with Prof. Kjell-Morten Myhr and Dr. Shamundeeswari Anandan. The project aims to define a potential MS-specific brain-derived blood exosomal biomarker panel to tailor rituximab treatment regimens to individual relapsing MS patients.



**Marie Ytterdal** joined the MS-Research Group in September 2024 after finishing her Master degree thesis on biomedical sciences at the UiB. She is currently employed as a researcher on a project studying potential regenerative effects in progressive MS from exosomes originated from for mesenchymal stem cells, and she has applied for a PhD candidacy.



**Elisabeth Evjenth** joined Neuro-SysMed in September 2024 after finishing her Master degree thesis on biomedical sciences at the UiB. She joined as a laboratory engineer, and she will also be responsible for the study of medication logistics at the centre.



# RECENT NEURO-SYSMED NEWS STORIES

NTB Info, 30.09.2024. [Åpner nytt senter for sammensatte sykdommer og aldring](#). Bettina Husebø.

Fredriksstad Blad, 28.09.2024. [Fredrikstad MS-forforening](#). Kjell-Morten Myhr.

NRK Innlandet, 27.09.2024. [Brukte 20 millioner kroner på et senter fagmiljøet ikke vil ha](#). Ole-Bjørn Tysnes.



Dagens Medisin, 20.09.2024. [Fikk «Young investigator award» for sitt bidrag på MS-kongress:- Veldig artig](#). Brit Ellen Rød.

HealthTalk, 19.09.2024. [Nye fireårs-resultater på MS-medisin:- Dette er gode data](#). Øivind Torkildsen.

Dagens Medisin, 19.09.2024. [MS-legemidler:- En vellykket norsk strategi](#). Øivind Torkildsen.



## MS-legemidler:- En vellykket norsk strategi

Vi ser en effekt som er mye større enn det som er vist tidligere, sier professor og overlege Øivind Torkildsen. Omstilling presenterer nye baselinedata fra OVERLORD MS-studien på årets ECTRIMS kongress.

Bergensavisen, 15.09.2024. [Lokal seniorlandsby vekker oppsikt](#). Bettina Husebø. Også i Fanaposten, 13.09.2024. - [Her er det mye å hente inspirasjon fra. Den lokale seniorlandsbyen vekker oppsikt](#). Bettina Husebø.

Helse Bergen, 03.09.2024. [Haukeland stiller sterkt på Forskningsdagene 2024](#). Neuro-SysMed.

HealthTalk, 19.08.2024. [MS-forskerne åpner for fremtidig kur - men det blir langt frem i tid](#). Kjell-Morten Myhr og Øivind Torkildsen.



MS-forskerne åpner for fremtidig kur - men det blir langt frem i tid

Norske MS-eksperter trekker fram mange store utfordringer innen behandling av multipel sklerose (MS).

Gudbrandsdølen Dagingen, 30.07.2024. - [Spennende å være med på utviklingen. Lovende framskritt i MS-behandling](#). Lars Bø.



Labiotech, 04.07.2024. [Parkinson's disease: biotech's pursuit for more therapies](#). Charalampos Tzoulis.



Fosna-Folket, 02.07.2024. - [Jeg lurte meg selv. Ingen skulle vite om den alvorlige sykdommen](#). Lars Bø.

Bergens Tidende, 17.06.2024. [Her kommer eldreboliger med plass til studenter. - Vi vil avlaste det offentlige](#). Bettina Husebø.

Helse Bergen, 14.06.2024. [Gler seg over høy aktivitet ved Neuro-SysMed](#). Kjell-Morten Myhr, Charalampos Tzoulis.



Universitetet i Bergen CCBIO, 07.06.2024. [Brukermedvirkning i kreftforskning er fremdeles under utvikling](#). Neuro-SysMed-kurs.

Universitetet i Bergen CCBIO, 07.06.2024. [En viktig møteplass for brukere og forskere i medisinsk og helsefaglig forskning](#). Neuro-SysMed-kur.

Bergens Tidende, 07.06.2024. [Syv triks for å få et \(nesten\) evig liv](#). Bettina Husebø.



ImProntalaQuila.com, 30.05.2024. [Sclerosi multipla, ogni anno solo in Italia colpisce 3.600 persone](#). Kjell-Morten Myhr. The same in 17 other Italian media.

ClicMedicina, 29.05.2024. [Congresso FISM 2024. Salute del cervello e prevenzione della sclerosi multipla. Nuovi criteri per diagnosi e trattamenti](#). Kjell-Morten Myhr. The same in Terris - News Online 30.05.2024, og StraNotizie. it 29.05.2024.

Pledge Times, 28.05.2024. [Multiple Sclerosis Week, the Fism Congress on prevention and early diagnosis in Rome](#). Kjell-Morten Myhr. Same article in 13 other Italian media.

VG, 07.05.2024. [For Thea Marlene \(23\) endte kysseysken i kronisk utmattelse](#). Kjell-Morten Myhr.



## For Thea Marlene (23) endte kysseysken i kronisk utmattelse

For de fleste er viruset ufarlig. Men noen blir veldig syke. For Thea Marlene A. Jensen (23) endret kysseysken alt.

## DID YOU KNOW..

We are currently in process of changing our main website portal to Helse Bergen's, hence new and more effective and intuitive web pages will soon be available!



### Neuro-SysMed – eit senter for klinisk behandling av og forskning på neurologiske sjukdommar

Neuro-SysMed er eit forskingssenter for klinisk behandling (FKB) i Norge som fokuserer på tre sjukdommar: multipel sklerose (MS), Parkinsons sjukdom (PS), amyotrofisk lateral sklerose (ALS) og demens.

Finn våre aktuelle kliniske studiar



Kjende studiar hos Neuro-SysMed

Forskningsgrupper



Forskningsgrupper

Les om brukarrådet og om brukarane si rolle i forskning



Praksisveivert brukarleding informasjonsmateriell

Sjå kalender med våre aktuelle arrangement



Arrangementkalender

Les meir om oss



Om oss

Did you also know that our EBV-MS project has established its separate project website? Targeting the Epstein-Barr virus to treat and prevent MS (EBV-MS) is a groundbreaking Horizon Europe-funded research project with leading universities and hospitals in Europe and the USA. We are aiming to unveil the role of the Epstein-Barr virus (EBV) in the onset and progression of the Multiple Sclerosis (MS) disease. [You can find the EBV-MS website here.](#)



## EBV-MS

You should also notice that Neuro-SysMed has established a LinkedIn page where we will send information regularly. You should definitely follow us!



### Neuro-SysMed

A Norwegian centre at the UiB/Haukeland University Hospital for clinical treatment research on neurological diseases.

## CONTACT

### Centre co-Directors

Kjell-Morten Myhr, Centre Director  
[kjell-morten.myhr@helse-bergen.no](mailto:kjell-morten.myhr@helse-bergen.no)

Charalampos Tzoulis, Centre Co-Director  
[charalampos.tzoulis@helse-bergen.no](mailto:charalampos.tzoulis@helse-bergen.no)

### Centre Coordinator

Mona Machrouh  
[mona.machrouh@uib.no](mailto:mona.machrouh@uib.no)  
+47 55 58 91 11

### Research Adviser

Yamila Torres Cleuren  
[Yamila.cleuren@uib.no](mailto:Yamila.cleuren@uib.no)  
+47 55 58 54 31

### Research School Coordinator

Nina Grytten Torkildsen  
[nina.agnethe.grytten.torkildsen@helse-bergen.no](mailto:nina.agnethe.grytten.torkildsen@helse-bergen.no)

### Communications Officer

Eli Synnøve Vidhammer  
[eli.vidhammer@uib.no](mailto:eli.vidhammer@uib.no)

### General inquiries

[Post@neuro-sysmed.no](mailto:Post@neuro-sysmed.no)

### Website

[Neuro-sysmed.no](http://Neuro-sysmed.no)

### Events calendar

<https://www.uib.no/en/neuro-sysmed/calendar>



Neuro-SysMed



Centre for  
Clinical Treatment  
Research



Haukeland University Hospital

